Introducing "The Year in Review Recordings", a series where we reflect on the past year and look forward to the coming one. Hosted by Christian Soschner, this podcast brings you expert speakers from previous episodes and partners of the podcast to give you an in-depth analysis of the latest advancements in their fields and an outlook for the future. This is the 6th conversation in the series. In this episode, we have Dr. Collin Y. Ewald, founder and president of the Swiss Society for Aging Research and head of the Extracellular Matrix Regeneration Laboratory at the Department of Health Sciences and Technology. Dr. Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. He is a leading expert in the field and has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences. He is named among the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland. We'll be discussing Dr. Ewald's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages. We'll also be discussing the Ewald Lab's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages. This episode also includes topics such as Longevity Research and Horizon Europe, How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages, The 9 Hallmarks of Ageing, Solving the Clinical Trial Challenges in Longevity Research, Food Supplements for Longevity in 2023, Collin Ewald’s Spin Out Company, The 10 Simple Rules to Start a Successful Spin-Off Company, 2023 in Longevity Research - Upcoming Trends. Don't miss out on this episode of "The Year in Review Recordings," where we dive into the world of longevity research with Dr. Collin Y. Ewald and stay informed about the latest advancements in the field. 💡 LINKS TO MORE CONTENT. If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe Podcast Episodes: https://pod.link/1493847125 Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2 Watch on Youtube Collin Ewald Christian Soschner ⏰ Timestamps: (00:00) Intro (03:00) Welcome Note Collin Ewald (04:25) Longevity Highlights in 2022 in the Ewald Lab, ETH Zurich (07:08) Published Results of a 9 year study to understand the mTOR Kinase and its role in ageing better (08:52) Longevity Research and Horizon Europe (11:08) How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages? (14:35) Highlights in the Longevity Research Area in 2022 (17:08) The 9 Hallmarks of Ageing (23:17) Solving the Clinical Trial Challenges in Longevity Research (25:09) Food Supplements for Longevity in 2023 (28:37) Collin Ewald’s Spin Out Company (30:37) The 10 Simple Rules to Start a Successful Spin Off Company (35:49) 2023 in Longevity Research - Upcoming Trends Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Christian SoschnerAre you ready to unlock the secrets of healthy aging and longevity? Then this episode is for you.
Collin EwaldNews article, right? And people will use the knowledge, of course, to move it forward. But usually in the last sentence of the paper is that we with this we could you know solve this and that problem, right? But the translational part is never really done. And that's the reason the reason is because there's no no incentive for an academic researcher to translate anything. Because you know, you as an academic, you judge by the high impact papers you do, right? But not what you you bring to the market, what impact you you do or you bring to the people, right?
Collin EwaldAnd my goal is actually to whatever I find in the research to actually also bring to the people.
Christian SoschnerI mean that's one of the Welcome to the third edition of The Beginner's Mind year in review recordings, where we reflect on the past year and look forward to the coming one. I think in the third year I can start calling it a tradition. Before Christmas, I invite speakers from previous episodes and partners of the podcast to reflect on the last year and give an outlook on the coming one. Between the Western New Year and the Chinese New Year, each speaker gets their own episode as a starter into a successful future.
Christian SoschnerI'm your host, Christian Soshna, and I'm excited to bring you the sixth conversation in the series of 2022. Joining me today is Dr. Colin Ewald, founder and president of the Swiss Society for Aging Research and head of the Extracellular Matrix Regeneration Laboratory at the Department of Health Sciences and Technology at the ETH Zurich.
Christian SoschnerColin is a leading expert in the molecular biology of healthy aging and age-related pathologies, and has received multiple awards for his work, including a recognition as a future entrepreneur and a spot on the list of the world's top 1,000 longevity leaders. Today we will be discussing the Everett Labs' recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages.
Christian SoschnerSo sit back, relax, and let's dive into the world of longevity research with Dr. Colin Ewald. Hi Colin, good to see you.
Collin EwaldHow are you doing? Great. No break, no nothing. So I think you're doing great there.
Christian SoschnerNo break yet. Let's see. We have uh one and a half hour to go. So it's uh it's over, it's over Zoom. Colin, how is life in in Switzerland these days?
Collin EwaldI would say it's good. We had lots of snow here in Zurich a couple of days ago, and now it gets really warm, which I don't like because uh I will go skiing and snowboarding over Christmas, and now the snow is melting, and I'm getting really, really worried. But you know, these are you know minor problems, but still I look forward to the holidays.
Christian SoschnerSummer is coming back in Switzerland over the holidays. Yeah, hopefully not. I saw it also in Vienna on the better forecast that we get 10, 11, 12 degrees.
Kimberly CornfieldI prefer the colder weather as well, Colin. It's a bit warm.
Collin EwaldIt's really amazing because it was always it was minus degrees, right? We had minus eight, minus ten, minus three, and now it's warming up again. Right.
Christian SoschnerColin, what were your highlights in 2022?
Collin EwaldWell, you know, as an academic researcher, of course, my highlights are you know publishing really cool papers.
Christian SoschnerWhat was your coolest paper?
Collin EwaldThe coolest paper was actually one that took nine years to get out and publish, right? So these are these journeys you do as an academic. So as we started in 2013 and looking how when you reduce um m-TOR signaling, which is better known, like if you take a truck like Rapomycin, right? The m-TOR kiness is really important for aging and longevity, and uh, you know, people some people are already taking it, right? And there's a lot of research done on on that important kiness.
Collin EwaldAnd we know that we do sin uh reduced TOR signaling, you know, you activate out of AG, which is recycling. But one part was not understood is like you, you know, you also reduce protein translation. And so we it took us really nine years to figure out how that actually works and how the mTOR uh downregulation signals across uh cell types, right? Because you look at whole organism. So um we figured out then that there's a special pathway activated and actually works to hydrogen sulfate, which is really surprising, right?
Collin EwaldAnd so this hydrogen sulfate actually signals across tissue and gives you all the health benefits, um, which we can maybe talk later a little bit more. But that was really, you know, a long winding road down, lots of dead ends, and we're really happy that finish managed and we were finally able to publish it.
Christian SoschnerNine years, nine years. How how how how how was the work process to keep motivated for nine years to keep the work behind the publication going?
Collin EwaldYeah, you know, I started this as a postdoctoral researcher at Harvard, and um we just everything looked good, but you know, you want to figure out you want to figure out the mechanism, right? And always you think like, ah, just a little bit more, this experiment, that experiment, then you you then you have it, right? And you you just keep on it and come up with new ideas. And I was almost giving up on it uh until I met another researcher, Alvin Longchamp, he is at the University of Lausanne. He's uh he's a clinician, and he said, you know, I think it's working through this uh transcription factor ATF 4, which is an activation transcription factor, really important for homeostasis, right?
Collin EwaldAnd I said, Yeah, all right, you know what? I prepare the experiment, I bring it over to your lab, right? It's only a short train ride, about three hours from Zurich to Lausanne. You guys try to do the experiments and it just worked out, and everything started to fall in place. And so that's why you get the new shoop into these kind of projects and move it forward across the finish line.
Christian SoschnerI can believe what's going on uh in the longevity research at the UCL. Do you have uh also a specialization in that area?
Kimberly CornfieldI I do not, not in our not in our horizon portfolio. That's why I'm really interested to hear more about um your work, Colin, and and what you're doing. Um, and really nine years. I was gonna say that sort of that takes a lot of um patience and dedication to keep keep that going. So really interesting that this researcher has another researcher um sort of inspired you to keep keep going.
Collin EwaldYeah, and and so that's just also how science works, right? You because you talk with other scientists and during the pandemic, there was you know, it's not really happening. Now finally we have meetings and conferences again and exchange ideas, right? And you know, you struggle with something and suddenly somebody has a cool idea. But I mean, you know, I'm I'm also curious, you know, why why do you think there is no you know, you know um weight late to aging research in in in in in your areas or you know, why why do you ask?
Collin EwaldBecause I think aging research is coming more and more up, right? And there are different programs there. And so I just curious also to hear from you. So I can ask questions. Go ahead. Go ahead.
Kimberly CornfieldAbsolutely. We do have our Institute of Healthy Aging at UCL, so we do have a lot of research. And I think there is um there is more and more happening in that space. And I think especially if we're looking at we're living longer and sort of that impact as well. So there is, you know, there is research research funding in that space of that impact. I think there's an economic impact that research, you know, that where research funding is looking at that as well. Um, and I think it's gonna, you know, it's increasingly, as you say, becoming more and more important.
Collin EwaldAnd so so so how are these topics selected? Is it you know public interest or is it coming from the politicians or how or where does, or is it just the money flow?
Kimberly CornfieldIt's a lot of work goes in behind the scenes to prepare the work programs with politicians, with bringing on experts, I think individuals and organizations and researchers themselves will lobby for funding a specific topic. And then they do them for two years. And um, and hopefully, I think in the long term, uh having that funding flow to build on those successes as well. I know that that's something more and more of a focus. They've got the commission has this mission-oriented approach.
Kimberly CornfieldUm the one around health is more is on cancer, but it's sort of to try and link up these projects and build and support each other building on as well. So I think I'm really keen to see more research, more funding that supports sort of those next phases of development or continuing what we've got on. But yeah, just um a lot of a lot of work in the backdrop on the European Commission side to pull together those topic areas.
Collin EwaldAnd one more thing I wanted to ask because I'm just curious. You know, you mentioned interdisciplinary research, right? And from my side, I've, you know, work, I'm a I'm a biologist, right? And uh ETH CERC, it's a techno university, we have lots of engineers, right? And so for me as a biologist, talking to engineers or talking to mathematicians, because we also had a paper where we had computation, we have mathematics, we had engineering, we had physics, and we had biology, right? And and the and they're completely different languages.
Collin EwaldSo it's like you know, me speaking you know, German, the other person was speaking French, or so it's just it's completely different language, a completely different mindset. How do you bridge these and how do you translate and start the communication between the different disciplines?
Kimberly CornfieldIt's a really good point. And it's somewhat, I would say, part of what I do, I've done it a lot on the cross-sector element. So when businesses approach us um and how to connect, so we get pitch decks, and I say, can you instead of a pitch deck, can you give me a paragraph of what you want to do or what the research is? And then you can send this to, and I will send the pitch deck still to academics, but and then across disciplines as well. Um I've done less of the it the less of the mixing across disciplines directly, as I've done more on the cross-sector, which is and is learning the different languages.
Kimberly CornfieldUm, but I yeah, I it it's challenging. Um, and I think when when my team may help put these proposals together, I think we have a common language that has to be applied in these instances for what we're involved in, which is the European, the EU language. So it's sort of you bring in everyone's different languages and then we try and help put it together into an EU proposal and this sort of EU language. Um, I think that's one way where we're doing that, but it's definitely a challenge.
Kimberly CornfieldHave you no, can I ask a question? Have you been involved in any sort of European collaborations or funding?
Collin EwaldYeah, you know, it got really difficult for Switzerland, right?
Kimberly CornfieldOh, of course, sorry. There's some, there's some uh we have a sort of special connection on on that point.
Collin EwaldYeah, I know I wish. And it's really sad um to see that that, you know, you know, I mean it's a crawl great loss for Switzerland, also research, and I think also vice versa. I think the communication between uh the European uh and and the Swiss research institution um should be established again. Um, but I I'm not following that closely anymore.
Kimberly CornfieldThat's more of a what I'm following more closely, and we have a nice uh we collaborate a lot with ETH Zurich and a number of other Swiss institutions, and so we've got sort of between the UK and the Switzerland at the moment, there's a um a shared challenge and understanding.
Collin EwaldYeah, but coming back to your question, I you know, there is this um extra matrix and aging um network that's also coming from an aging network coming also from the UK. And there I'm acting as an advisor on the advisory board. And you know, coming up with these initiatives, what I learned it's very hard to state the mission statement, right? Where's you know, first you do this gap analysis, where where's the gap in knowledge, and then you try to formulate a mission statement, given with all the expertise and leverage you have from the individual groups, right?
Collin EwaldAnd so I think this is this is very challenging to to move this forward.
Christian SoschnerBut talking about longevity research, what were the big breakthroughs in the longevity research that uh you saw in 2022, besides uh your your great research? Where is uh uh the this area heading to?
Collin EwaldYeah, I mean I'm honestly not so happy with the longevity um research because it's at the moment still there's no clear vision or where to go, and you know, also for the assessment of the different findings, because I mean there are really cool breakthroughs, right? But sometimes, you know, the way it's read out or or how the claims made are a little bit too um too high, they're claiming too much for what they deliver, right?
Collin EwaldOr based on you know some of these findings. So I wish there was would be more um time or you know incentive to actually do a little better job. Um having said that, you know, there are so many uh interesting areas coming out. I mean, we had these uh nine hallmarks of aging that were defined in 2013, really um say what what the different aging processes are all about. And lately, more and more researchers realized that you know they're not only nine hallmarks of aging, of course, right?
Collin EwaldAnd there are more. And so, you know, more and more research gets gets into actually providing new hallmarks or you know, things to work on. And and for anybody to understand, hallmarks of aging is a is a concept, so you can easily understand what what's going on about it. And so in the cancer field, for example, it really started to to bloom when the hallmarks of cancer were defined, right? Because once you have a hallmark, you have a framework to to work with.
Collin EwaldAnd so for the aging, it's you know, there are these um damages to different parts of uh, for example, proteins or DNA, right? So these are more the causes of aging, and then the consequences for yourself or for your body, right? And so I think you know, in 2000, yeah, this year, I think there are new and new and more voices were lifted that you know there's more and more to come, which is exciting, right? Which just expands the whole horizon um and and things to uh to work on.
Collin EwaldAnd that also helps, you know, not only academic researchers, but also helps, you know, um startups, for example, right? Because you see, like, oh, this is a very important area to work on or in, and then how can you apply or solve that solution, right? So that is also then coming more there.
Christian SoschnerWhat what are the I'm curious now, what are the nine hallmarks of of aging?
Collin EwaldSo the first one um you know is you know the DNA, um the genome instability, right? So the DNA how it packed, and are on the end of the DNA, there are these telmorases where uh these are like in your shoelaces, if you know the knots in the shoelaces. And so if they go off, then then your shoelaces go really, right? And something like similar happens to your uh chromosomes, right, which is your genome, right? Because every time you sell device, it has to pack it again and then unpack it, right? And so these are important.
Collin EwaldYou lose always a little bit of these telomerases, and then so that's damage to the DNA itself, but then the DNA has to be also red, and that's called um epigenetic regulation, which epigenetic is standing on top of it, right? And so that's this you have your blueprint, but also environment is important. If you go and do exercise, right, the epigenome will be changed, adapting to the stress from the exercise, right? And so that's the epigenetic regulation that's also lost, and then you go further on to out of the DNA, right?
Collin EwaldThe message is getting out there, which gives you the proteins, right? And all those proteins have to maintain, they are like the building blocks, the enzymes that function your body, or the structural things, and those ones also have to be um holed together, and then you go further out into your cell, you have organelles like the mitochondria, which is the powerhouses, right? They also decline, so your energy metabolism declines that has important things for um nutrient sampsing, which is another hallmark there, and on a hormonal uh balance, and then also your cells can become senescent.
Collin EwaldSo cells have a limit how many times they can divide, also depending on the thermal races, and that's the senescence. And those cells actually accumulate in your body and also release, you know, other factors are not good. It's like having a rotten apple around all apples, so the rotten apple would get the other ones also, you know, become more rotten, right? So that's the analogy of these um senescent cells, which are zombie cells, and then um they of course are you know between the tissues or tissue maintenance are the stem cells, right?
Collin EwaldSo the stem cells start to exhaust, so you cannot regenerate your tissue, and then the communication between the tissues, I think I have understood that all nine hormars more or less try to um from the heroic side. And so you could technically start to address anything, right? So if you could you know uh maintain your stem cells for better better, right? Or this maintenance for better, then you could regenerate the tissue for longer and you could of course then live longer, right? Your skin could be younger for longer, if you get rid of senescent cells, you know, um that also um helps.
Collin EwaldAnd so the definition of these hormocks is usually that um it has to, you know, if if it's gone, it has to accelerate the aging process, but if you give it back, you can aggravate you can slow age, right? And usually in mice you want to see then it can extend the the lifespan of the mice. Yeah, so that's that's these are the definitions.
Christian SoschnerWhat is what is possible currently when we think about extending the lifespan uh with with uh the existing technology?
Collin EwaldSo okay, if you if you're a cell or a mouse, then we can do a lot of things, right? We can rejuvenate you completely, right? And uh and extend your lifespan. Um so far, you know, we're still on the translational side to humans. So at the moment, for us, it's unfortunate whatever your grandma said, you know, do exercise, eat right, sleep right, all those things uh is at the moment. The next steps are actually um supplements, you know, because you know they're not regulated, but also on the other side, they haven't really been proven in clinical trials yet, right?
Collin EwaldAnd hopefully then, you know, one day we will have, or like maybe in five, ten years, we would have drugs that would slow aging. At the moment, there's one of the uh drugs that is is good, it's called metformin, which is a type 2 diabetes drug. And researchers like Neo Basta use that to uh do a proof of concept or concept trial in a sense that because you know, if you think about aging, aging is not a disease.
Collin EwaldAnd so, how would you run this through a clinical trial where you have to target the disease? Okay, so now um there's lots of back and forth. Going in the field is very active, and the FDA now agreed that we could measure time to event, like how long would it take to get Alzheimer's disease or dementia or cardiovascular problems or type 2 diabetes, right? So all these committed How long would it take it on placebo?
Collin EwaldAnd how long would it take it on a longevity truck like metformin, right? So it does time to invent. And so hopefully those trials will start soon and we would have a blueprint to run actually clinical trials because you know, also our lab does research and we predict trucks that could that extend lifespan in model organisms, right? But then you want to have we want to actually translate that. And you know, you still have to go to um clinical trials if you want to do anything in the biotech sector or you know, something important.
Christian SoschnerGo ahead. It would be good to have a proof in a clinical trial. I still have a hard time to figure out uh to just uh think for how can a clinical trial work. I mean, the claim that I read very often or I see very often on LinkedIn, for example, Christian Angenmeier posts frequently about longevity, is that it clearly extends the lifespan uh until infinity. So basically you can live forever and decide when to end your life, uh, which would be a nice thing, uh, to live for 400 years and then say, okay, I had a good 400 four centuries and it's off. But how will you translate it in a clinical trial?
Christian SoschnerI mean, this this this would be long-running studies basically. You would go for a study of 10, 20, 30 years.
Collin EwaldYeah, yeah. Uh it's it's it's very difficult. At the moment, the way to move forward is that you take people that are you know around 70, 75 and a little bit uh frail. So frail means you know the the how fast they walk, the physical performance, and so they're really close to getting one of these age-related diseases. And then you just choose a window of five years, which is still a long time and costs a lot of money. Um, but that's at the moment uh the the way forward, at least what I've seen.
Collin EwaldUm, other than that, you just go by if you have if you know your target, right? You go by a disease, or you can go by an orphan disease or something like that. You can still go the classical way. Um, and but you know, the challenge really is all these biotechs also um that you know are in the space to have anything a therapeutic intervention or a medication, um they fail actually by at the clinical trial um kind of thing, because you know it's it's the design on one part and there's no real good good blueprint.
Collin EwaldThat's the the the the biggest challenge uh at the moment.
Christian SoschnerI've I forgot to say uh say say goodbye. Uh do you want to stay a couple of minutes or do you want to drop off?
Kimberly CornfieldMaybe I'll just I just have one question actually for Colin and then if you don't mind I'll then I'll drop off. But you mentioned supplements, which was quite interesting because it's it's not regulated the way drugs, well, it's not regulated, I think, most places. And so it's has there been a lot of interest kind of in the field from um companies or around supplements in this space that are in touch with with you or researchers in this area?
Collin EwaldYes, there's um there's huge interest again because that's the fastest you can bring um to the consumer to the market, right? And I have to um say a disclaimer here. I I'm a co-founder of the supplement company, and some research uh is actually spun out of my lab, which you know, which is pretty I'm I'm pretty excited about. Um so you know, you know, and and I tell you the reason from an academic side why I decided to do this, because as an academic, um, you know, you you do your research, which is great, you ask big questions, um, it's very exciting, and then you publish it and it gets to a paper.
Collin EwaldAnd the paper will be, you know, collecting dust after a couple of years, because you know, there's it's like a news article, right? And then it just collects dust, right? And people will use the knowledge, of course, to move it forward. But usually in the last sentence of the paper is like with this, we could you know solve this and that problem, right? But the translational part is never really done. And that's the reason the reason is because there's no no incentive for an academic researcher to translate anything. Because you know, you as an academic, you judge by the high impact papers you do, right?
Collin EwaldBut not what you you bring to the market, what impact you you do or you bring to the people, right? And my goal is actually to whatever I find in the research to actually also bring to the people. I mean, that's one of my main goals. And so we've done huge screens with different drugs, and we stumbled actually in those screens at the supplement, at the compound, that increased um the lifespan of C elegans, and it also um promoted the the collagen, so the proteins outside cells, the homeostasis.
Collin EwaldSo the turnover rate is actually declining during aging, and we show shown that actually it promotes it, right? So it made it made it really interesting. And so I had the decision to face either, you know, I you know I write it up, submit it, and it's out, right? Nothing will happen. But I thought, you know, this this looks too good to be true. I will I want to try it. But the problem is, as an academic researcher, you you cannot do this. So you have to um start, find people to you know do the company, and in the supplement space, um, it's really important that you have you know a really good team that promotes it forward, also to you know do the whole public relation and everything like that.
Collin EwaldSo I was actually happy to, as a scientist, say, okay, you can move the science forward and then spin it out. And so we want went on to pattern it and now it's spinned out and it will be released um, I think end of this year, um, which is which is really cool to to see really from from the bench to bed side is the wrong word, but you know, to to the people.
Christian SoschnerYou mentioned your spin-out. Uh so you're in the process of spinning out the technology into a company. Uh Kimberly, sorry if I forget I forget again.
Kimberly CornfieldThat's okay. I think I I have to drop off now, but thank you so much. I mean it was really interesting, and I'm congratulations on the spin-out. And um also just to note that that's actually a really uh selling factor in getting yourself collaborative grants in the EU is sort of also for having that company, that expertise, and and spin-out. So I'll leave it at there and to keep carrying on. But thank you so much both. It was great to chat and Merry Christmas, Happy New Year.
Christian SoschnerKiboli, Merry Christmas, Happy New Year. It was good to have you on the show. Thank you. Bye. Bye. Pauline, your spin-out. Uh, are you already um ready to talk about details, what the spin-out uh is all about? Uh, what's your goal with the spin-out?
Collin EwaldI I can't to to a certain extent, right? Um, I don't want to take away the the thunder or the fire or what you want to help me today, but um you know it's actually a compound that's that's an activator of you know collagen homeostasis, which really is one of the biggest challenges to XL matrix that declines during aging, you see with the skin, the sacking and the wrinkles, right? And um, you know, the only way I am aware of to rejuvenate or you know make this useful is when you do damage to it, because if you do damage to the XL matrix, right, it will start to repair, but that only works to a certain extent.
Collin EwaldSo having found you know a supplement that will uh do this is is really cool um to see because it's not only the collagens are not only in your skin but also in in your internal organs, right? So you assume that whatever you see on decay coming in the skin, you also have insight, and to both also this is actually really um really cool.
Christian SoschnerAnd so yeah, we need to do a podcast when you when you're completed with the spin-out process. So I hope that you're already uh there. Um what maybe I ask you one question: what was your biggest learning uh in spin-out? So when an academic has an idea and says, okay, we want to spin something out, um, and he comes to you and um wants to discuss and talk with you, uh how you how how you how you did it, uh, what were the challenges, uh, what was easy, what was difficult, uh, which advice would you give uh to this researcher?
Collin EwaldWell, you know, first of all, nothing is easy. Yeah, I mean, for a reason, I mean, um, so if you if an academic researcher comes to me as a postdoc or PhD student and says I want to spin out something, I wrote actually a review with um um Topias Reichmut about uh the 10 simple rules to start a successful um spin-off company. 10 commandments. So so yeah, I mean, uh you know, the so first of all, the the academic or the researcher mindset is completely different than the business mindset, right?
Collin EwaldAnd so you have as a researcher first have to learn something about business, right? If you have never done that, you have to understand what it means to um go fast to the market, right? So that means also you research what you do and has to be really focused because usually in academia you start somewhere and then oh, this is interesting, you go this way or this way, right? But you have to really stay on target. And so that that that's one thing you have you have to learn and just you know be very focused, right?
Collin EwaldUm to work.
Christian SoschnerIs that is that is that such a huge difference in this these two mindsets?
Collin EwaldI I think so, yeah. And it's it's really the discussion and the openness and learning uh something because it's just it's just these subtle things. I mean, sometimes you use the same words, but you completely mean something different, right? Because I mean, for an academic researcher, what is my incentive to put out research instead of doing good things? But I, as a researcher, care a lot what other people think of me, right? My peers, right? Do they think it's really cool innovation? This is novel, is it exciting, right?
Collin EwaldSo, what do other people think? And that's completely different, what you know, a you know, a CEO mindset will be, right? So, you know, you want to you have a vision, you want to drive it forward in a sense you have, you know, maybe the same mission to do something good, but you know, also other incentive. You want to, you know, commercialize things, right? Which is completely different to making something really cool and novel and the coolest technique. And also have to learn, you know, what the consumer wants or needs, right?
Collin EwaldThere's no need to make something super, super cool and fancy, which consumer won't understand, and it's not um I I mean I see this, but I think the I mean I can say the company is called Avea Life, um and the team is is really good. I mean, you know, we have these discussions where I come with my science statements and they come back, it's like it's way too complicated, right? And so we try to really like simplify the language to give the same meaning um to what it is, actually, right, and to to make it understandable.
Collin EwaldAnd that that's a skill I think researchers also lack in a sense to also to sell it, right? In a in a sense.
Christian SoschnerYeah, I had Albert Misby earlier today on a podcast. He is in the process of pivoting from P2P to B2C in diagnostics, and he also said something similar. He said the biggest challenge now is uh to translate the scientific language which was tailored for the B2P world now into the B2C world. And uh one of his comments was uh nobody in the B2C world reads more than three sentences, so you need to say everything that's relevant in three sentences.
Collin EwaldYeah, I saw that one. That was really uh impressive to me to uh to hear this, and uh it just resonates very well, right? It's just yeah, and I mean GO will have this elevator pitch, you have 15 seconds to put it down and put it into perspective and make it interesting, right? In a sense. What is the big launch plan for your new company? The the company is already launched, so they are already on the market. Uh so to bring that pro our product onto the market will be, I think, end of this this year, so soon-ish.
Collin EwaldUm oh, it's uh only two weeks left, so it's really soonish. Yeah, it's only two weeks left. And so this is really a new kind of uh of supplement, which is which is which is exciting uh to to come out. And you know, the thing is for me as a researcher, I know it's safe. So we also have done all these experiments in mice, and we actually done the experiments in very old mice. Because you know, usually those experiments are done in young mice and they're very resilient, right? And you know, and their old personal mouse is completely different because all these defense mechanisms don't work so well anymore.
Collin EwaldAnd so these old mice, um, you know, we've given them to the old mice, they improve their frailty. So they this pre-clinical assessment, they have better crib spramp and you know, fatality, and you see this health permit, which is really exciting uh and rewarding to see, actually, right?
Christian SoschnerUm that's great to hear. That's good to hear. Um, in the last minute, uh time price. This is this is a big problem with this podcast, uh, with interesting speakers. Uh, it just goes by in no time. Um one final question predictions for 2023 in the longevity space in your area of research. Where what what will we see in 2023 besides your new company?
Collin EwaldYeah, I think you know there's a lot of work done on uh rejuvenation in a sense, right? So with these um Yamunaka factors, and I think hopefully we we find something, another approach to do the same thing, but clearly what is needed is not only the slowing of aging, but also the regeneration of tissue or even whole organs. And I've I hope that more cool research will come out uh in in that area.
Christian SoschnerYeah, hopefully it would be interesting to see to come really to that point, like Christian Angermeyer says, that uh human beings can decide how long they want to live, would be a good thing. Colin, let me pull in the next speaker for a brief introduction. Um, it's Guido Guardoni from Don't miss out on valuable insights and information. Hit the subscribe button now to stay updated on our latest episodes and join our growing community of like minded individuals.
Christian SoschnerYour support helps us reach more people who can benefit from the content. Show your support by liking, commenting, and sharing the episodes. Thank you for being part of our journey.
Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...
The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...
In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...
A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...
What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...